Molecular engineering and design of therapeutic antibodies.
暂无分享,去创建一个
[1] Sachdev S Sidhu,et al. Molecular recognition by a binary code. , 2005, Journal of molecular biology.
[2] P. Parren,et al. Anti-Inflammatory Activity of Human IgG4 Antibodies by Dynamic Fab Arm Exchange , 2007, Science.
[3] G. Georgiou,et al. APEx 2-hybrid, a quantitative protein–protein interaction assay for antibody discovery and engineering , 2007, Proceedings of the National Academy of Sciences.
[4] A. Lawson,et al. A single amino acid substitution abolishes the heterogeneity of chimeric mouse/human (IgG4) antibody. , 1993, Molecular immunology.
[5] C. T. Hehir,et al. Reduction of IgG in nonhuman primates by a peptide antagonist of the neonatal Fc receptor FcRn , 2008, Proceedings of the National Academy of Sciences.
[6] R. Ober,et al. Engineering the Fc region of immunoglobulin G to modulate in vivo antibody levels , 2005, Nature Biotechnology.
[7] Philippe Mondon,et al. Human antibody libraries: a race to engineer and explore a larger diversity. , 2008, Frontiers in bioscience : a journal and virtual library.
[8] T. Schneider-Merck,et al. Effector Mechanisms of Recombinant IgA Antibodies against Epidermal Growth Factor Receptor1 , 2007, The Journal of Immunology.
[9] Brian Mohan Gurbaxani,et al. Development of new models for the analysis of Fc-FcRn interactions. , 2006, Molecular immunology.
[10] Herren Wu,et al. Modulation of the Effector Functions of a Human IgG1 through Engineering of Its Hinge Region , 2006, The Journal of Immunology.
[11] Leonard G. Presta,et al. High Resolution Mapping of the Binding Site on Human IgG1 for FcγRI, FcγRII, FcγRIII, and FcRn and Design of IgG1 Variants with Improved Binding to the FcγR* , 2001, The Journal of Biological Chemistry.
[12] Herren Wu,et al. Properties of Human IgG1s Engineered for Enhanced Binding to the Neonatal Fc Receptor (FcRn)* , 2006, Journal of Biological Chemistry.
[13] R. Aalberse,et al. The inter-heavy chain disulfide bonds of IgG4 are in equilibrium with intra-chain disulfide bonds. , 2001, Molecular immunology.
[14] Frederic A. Fellouse,et al. High-throughput generation of synthetic antibodies from highly functional minimalist phage-displayed libraries. , 2007, Journal of molecular biology.
[15] P. Baeuerle,et al. Exchanging human Fcγ1 with murine Fcγ2a highly potentiates anti-tumor activity of anti-EpCAM antibody adecatumumab in a syngeneic mouse lung metastasis model , 2007, Cancer Immunology, Immunotherapy.
[16] A. Wu,et al. Tunable pharmacokinetics: modifying the in vivo half-life of antibodies by directed mutagenesis of the Fc fragment , 2006, Nature Protocols.
[17] L. Weiner,et al. Regulation of Antibody-Dependent Cellular Cytotoxicity by IgG Intrinsic and Apparent Affinity for Target Antigen1 , 2007, The Journal of Immunology.
[18] G. Winter,et al. Repertoires of aggregation-resistant human antibody domains. , 2007, Protein engineering, design & selection : PEDS.
[19] G. Winter,et al. Thermodynamically stable aggregation-resistant antibody domains through directed evolution. , 2008, Journal of molecular biology.
[20] G. A. Lazar,et al. Engineered antibody Fc variants with enhanced effector function. , 2006, Proceedings of the National Academy of Sciences of the United States of America.
[21] Leonard G Presta,et al. Enhanced half-life of genetically engineered human IgG1 antibodies in a humanized FcRn mouse model: potential application in humorally mediated autoimmune disease. , 2006, International immunology.
[22] J. Stavenhagen,et al. Fc optimization of therapeutic antibodies enhances their ability to kill tumor cells in vitro and controls tumor expansion in vivo via low-affinity activating Fcgamma receptors. , 2007, Cancer research.
[23] D. Altmann,et al. HLA-DR and H-2E transgenes differentially mediate TCR-specific positive selection. , 1993, International immunology.
[24] R. Aalberse,et al. Serologic aspects of IgG4 antibodies. II. IgG4 antibodies form small, nonprecipitating immune complexes due to functional monovalency. , 1986, Journal of immunology.
[25] Ying Tang,et al. Monoclonal Antibody Clearance , 2007, Journal of Biological Chemistry.
[26] Roy Jefferis,et al. Antibody therapeutics: , 2007, Expert opinion on biological therapy.
[27] R. Brodsky,et al. Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria , 2007, Nature Biotechnology.
[28] A. Nesbitt,et al. Prolonged in vivo residence times of antibody fragments associated with albumin. , 2001, Bioconjugate chemistry.
[29] A. Constantinou,et al. Modulation of antibody pharmacokinetics by chemical polysialylation. , 2008, Bioconjugate chemistry.
[30] Charles L Brooks,et al. Albumin binding to FcRn: distinct from the FcRn-IgG interaction. , 2006, Biochemistry.
[31] Herren Wu,et al. Development of motavizumab, an ultra-potent antibody for the prevention of respiratory syncytial virus infection in the upper and lower respiratory tract. , 2007, Journal of molecular biology.
[32] R. Dodge,et al. Evaluation of immunogenicity of the T cell costimulation modulator abatacept in patients treated for rheumatoid arthritis. , 2007, The Journal of rheumatology.
[33] D. Pearl,et al. The Major Histocompatibility Complex–related Fc Receptor for IgG (FcRn) Binds Albumin and Prolongs Its Lifespan , 2003, The Journal of experimental medicine.
[34] Min Zhang,et al. The pharmacokinetics of an albumin-binding Fab (AB.Fab) can be modulated as a function of affinity for albumin. , 2006, Protein engineering, design & selection : PEDS.
[35] J. Salfeld,et al. Isotype selection in antibody engineering , 2007, Nature Biotechnology.
[36] R. Kontermann,et al. A novel tri-functional antibody fusion protein with improved pharmacokinetic properties generated by fusing a bispecific single-chain diabody with an albumin-binding domain from streptococcal protein G. , 2007, Protein engineering, design & selection : PEDS.
[37] Sachdev S Sidhu,et al. Synthetic antibodies from a four-amino-acid code: a dominant role for tyrosine in antigen recognition. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[38] A. Datta-Mannan,et al. Humanized IgG1 Variants with Differential Binding Properties to the Neonatal Fc Receptor: Relationship to Pharmacokinetics in Mice and Primates , 2007, Drug Metabolism and Disposition.
[39] S. Langermann,et al. Increasing the Affinity of a Human IgG1 for the Neonatal Fc Receptor: Biological Consequences1 , 2002, The Journal of Immunology.
[40] L. Matis,et al. Humanized porcine VCAM-specific monoclonal antibodies with chimeric IgG2/G4 constant regions block human leukocyte binding to porcine endothelial cells. , 1997, Molecular immunology.
[41] Laurentiu M. Pop,et al. The generation of immunotoxins using chimeric anti-CD22 antibodies containing mutations which alter their serum half-life. , 2005, International immunopharmacology.
[42] George Georgiou,et al. Anchored periplasmic expression, a versatile technology for the isolation of high-affinity antibodies from Escherichia coli-expressed libraries. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[43] Ying Tang,et al. Ultra-potent antibodies against respiratory syncytial virus: effects of binding kinetics and binding valence on viral neutralization. , 2005, Journal of molecular biology.
[44] N. Tsurushita,et al. An Engineered Human IgG1 Antibody with Longer Serum Half-Life , 2006, The Journal of Immunology.
[45] Jonghan Kim,et al. Perspective-- FcRn transports albumin: relevance to immunology and medicine. , 2006, Trends in immunology.
[46] J. Foote,et al. Immunogenicity of engineered antibodies. , 2005, Methods.
[47] Damon L. Meyer,et al. Antibody targeting of B-cell maturation antigen on malignant plasma cells , 2007, Molecular Cancer Therapeutics.
[48] Sahana Bose,et al. Simultaneous targeting of multiple disease mediators by a dual-variable-domain immunoglobulin , 2007, Nature Biotechnology.
[49] S. Morrison,et al. Analysis of a family of antibodies with different half-lives in mice fails to find a correlation between affinity for FcRn and serum half-life. , 2006, Molecular immunology.
[50] R. Kontermann,et al. Improved Pharmacokinetics of Recombinant Bispecific Antibody Molecules by Fusion to Human Serum Albumin* , 2007, Journal of Biological Chemistry.
[51] G. Winter,et al. Engineering aggregation-resistant proteins by directed evolution. , 2006, Protein engineering, design & selection : PEDS.
[52] P. M. Davis,et al. Abatacept binds to the Fc receptor CD64 but does not mediate complement-dependent cytotoxicity or antibody-dependent cellular cytotoxicity. , 2007, The Journal of rheumatology.
[53] D. Burton,et al. Antigen selection from an HIV-1 immune antibody library displayed on yeast yields many novel antibodies compared to selection from the same library displayed on phage. , 2007, Protein engineering, design & selection : PEDS.
[54] George Georgiou,et al. Isolation of engineered, full-length antibodies from libraries expressed in Escherichia coli , 2007, Nature Biotechnology.
[55] R. Van Ree,et al. Normal human immunoglobulin G4 is bispecific: it has two different antigen‐combining sites , 1999, Immunology.
[56] G. Winter,et al. Aggregation-resistant domain antibodies selected on phage by heat denaturation , 2004, Nature Biotechnology.
[57] J. Tso,et al. Engineered Human IgG Antibodies with Longer Serum Half-lives in Primates* , 2004, Journal of Biological Chemistry.
[58] S. Akilesh,et al. FcRn: the neonatal Fc receptor comes of age , 2007, Nature Reviews Immunology.
[59] D. Goldenberg,et al. Characterization of a humanized IgG4 anti-HLA-DR monoclonal antibody that lacks effector cell functions but retains direct antilymphoma activity and increases the potency of rituximab. , 2006, Blood.
[60] R. Kontermann,et al. N-Glycosylation as Novel Strategy to Improve Pharmacokinetic Properties of Bispecific Single-chain Diabodies* , 2008, Journal of Biological Chemistry.
[61] Sachdev S Sidhu,et al. The intrinsic contributions of tyrosine, serine, glycine and arginine to the affinity and specificity of antibodies. , 2008, Journal of molecular biology.
[62] R. Stevens,et al. Molecular evolution of antibody cross-reactivity for two subtypes of type A botulinum neurotoxin , 2007, Nature Biotechnology.
[63] R. Ober,et al. Divergent activities of an engineered antibody in murine and human systems have implications for therapeutic antibodies , 2006, Proceedings of the National Academy of Sciences.
[64] A. Kretz-Rommel,et al. Blockade of CD200 in the Presence or Absence of Antibody Effector Function: Implications for Anti-CD200 Therapy , 2008, The Journal of Immunology.